Results 91 to 100 of about 51,654 (292)
Computational modeling of in-stent restenosis: Pharmacokinetic and pharmacodynamic evaluation [PDF]
arXiv, 2023 Persistence of the pathology of in-stent restenosis even with the advent of drug-eluting stents warrants the development of highly resolved in silico models. These computational models assist in gaining insights into the transient biochemical and cellular mechanisms involved and thereby optimize the stent implantation parameters.
arxiv
Ischaemic Heart Disease Masquerading as Headache: A Case Series
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Headache is a rare yet clinically significant presentation of ischaemic heart disease (IHD). While chest pain is the hallmark symptom of myocardial ischaemia (MI), some patients present with atypical symptoms, such as headaches, which lead to diagnostic challenges and potential delays in treatment.
Ibrahim Antoun +3 more
wiley +1 more source
Revista Colombiana de Cardiología, 2012 Introducción y objetivos: los stents convencionales presentan tasas de restenosis intrastent entre 10% y 60%, mientras los stents liberadores de fármacos alcanzan el 10%. Para Latinoamérica, no hay reportes de restenosis intrastent en comparación con los
Jorge A Arroyave C, Magda C Cepeda G
doaj
Nature CommunicationsDrug-eluting stent implantation suppresses the excessive proliferation of smooth muscle cells to reduce in-stent restenosis. However, the efficacy of drug-eluting stents remains limited due to delayed reendothelialization, impaired intimal remodeling ...
Haoshuang Wu +9 more
doaj +1 more source
Cardiology Research and Practice, 2020 Coronary heart disease is a major cause of death and disability in developed countries. Stent implantation has become an efficacious treatment for a culprit lesion vessel of the coronary artery.
Dai-Min Zhang, Shaoliang Chen
doaj +1 more source
MODELING DRUG ELUTING STENTS FOR CORONARY ARTERY BIFURCATION CONSIDERING NON-NEWTONIAN EFFECTS [PDF]
, 2020 1 Drug Eluting Stents (DES) are commonly used for the treatment of stenotic arteries. Restenosis can be treated by delivering anti-thrombotic and anti-proliferative drugs to the arterial wall.
Marjan Molavi Zarandi +2 more
core
A general model of coupled drug release and tissue absorption for drug delivery devices [PDF]
, 2015 In this paper we present a general model of drug release from a drug delivery device and the subsequent transport in biological tissue. The model incorporates drug diffusion, dissolution and solubility in the polymer coating, coupled with diffusion ...
Mcginty, Sean, Pontrelli, Giuseppe
core +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Coronary stent fractures (SFs) are an emerging complication of coronary stents. There are numerous risk factors for SF, which include vessel angulation, use of sirolimus‐eluting stent (SES), long stents, multiple stent layers, stent overlap, inflammation, hypersensitivity, stenting in the right coronary artery, heavy calcification, ostial ...
Kosuke Muto +3 more
wiley +1 more source
Bioresorbable vascular scaffold for coronary in-stent restenosis: A novel concept
Indian Heart Journal, 2014 The management of patients with significant in-stent restenosis (ISR) with drug-eluting stent is still not well defined. Various treatment modalities include plain old balloon angioplasty (POBA), metallic stent, cutting or scoring balloon and drug ...
Surender Deora +3 more
doaj +1 more source
Stent implant follow-up in intravascular optical coherence tomography images [PDF]
, 2009 The objectives of this article are (i) to utilize computer methods in detection of stent struts imaged in vivo by optical coherence tomography (OCT) during percutaneous coronary interventions (PCI); (ii) to provide measurements for the assessment ...
Carlier, Stephane Guy +4 more
core +2 more sources